Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
| Revenue (TTM) | $2.59B |
| Gross Profit (TTM) | $1.35B |
| EBITDA | $410.90M |
| Operating Margin | 11.80% |
| Return on Equity | 14.30% |
| Return on Assets | 1.50% |
| Revenue/Share (TTM) | $96.45 |
| Book Value | $282.74 |
| Price-to-Book | 1.30 |
| Price-to-Sales (TTM) | 3.96 |
| EV/Revenue | 3.732 |
| EV/EBITDA | 6.30 |
| Quarterly Earnings Growth (YoY) | 18.70% |
| Quarterly Revenue Growth (YoY) | 0.50% |
| Shares Outstanding | $21.83M |
| Float | $21.47M |
| % Insiders | 16.30% |
| % Institutions | 89.84% |
Volatility is currently expanding
Bio-Rad Laboratories NYSE: BIO reported modest third-quarter revenue growth, its first currency-neutral increase of 2026, as gains in clinical diagnostics and digital PCR instruments helped offset weakness in parts of its life sciences business.
Bio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call Transcript
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during the UBS Global Healthcare Conference on Tuesday, November 10, 2026, at 8:00 AM Eastern Time. A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad's website at i.
ZBRA's revenue growth accelerated across end markets and geographies, while margins and earnings exceeded expectations. CRL's results reflected improving demand across biopharma and biotechnology customers. Bio-Rad's shares also benefited from the announcement of a broad restructuring program designed to streamline operations and enhance profitability.
Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.
Bio-Rad Laboratories (BIO) remains a Buy, after my assessment of relevant corporate disclosures at the recent Wells Fargo Healthcare conference. Management targets long-term operating margins of 20%, with intermediate milestones in the mid-teens, outpacing consensus expectations. Margin drivers include cost rationalization, AI-driven efficiencies, and a shift toward higher-margin consumables revenue.
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo's 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relati.
BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BIO and any ticker you trade — then tracks every position and per-strategy win rate.
